Incorporating Bevacizumab and Erlotinib in the Combi Nonâ€“Small-Cell Lung Cancer: Results of a Phase I/II T

Journal of Clinical Oncology

30, 3953-3959

DOI: 10.1200/jco.2012.41.9820

Citation Report

#	Article	IF	Citations
1	Biologically Targeted Therapies Plus Chemotherapy Plus Radiotherapy in Stage III Nonâ€“Small-Cell Lung Cancer: A Case of the Icarus Syndrome?. Journal of Clinical Oncology, 2012, 30, 3909-3912.	0.8	7
2	The Role of Consolidation Treatment in Locally Advanced Unresectable NSCLC. Current Oncology Reports, 2013, 15, 424-432.	1.8	3
3	Design and conduct of early-phase radiotherapy trials with targeted therapeutics: Lessons from the PRAVO experience. Radiotherapy and Oncology, 2013, 108, 3-16.	0.3	14
4	Promising new molecule-targeted therapies and their integration into radiotherapy for lung cancer. Reports of Practical Oncology and Radiotherapy, 2013, 18, S18-S19.	0.3	0
5	Oncology Scanâ€”Promising Strategies for the Treatment of Locally-Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, 1-4.	0.4	14
6	Molecularly Targeted Therapies in Locally Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2013, 14, 467-472.	1.1	9
7	Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer. European Respiratory Journal, 2013, 42, 1119-1133.	3.1	14
9	Management of Normal Tissue Toxicity Associated With Chemoradiation (Primary Skin, Esophagus, and) Tj ETQq1 1 0.784314 rgBT /Ov	1.0	36
10	Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?. Therapeutic Advances in Medical Oncology, 2013, 5, 249-270.	1.4	38
11	Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review. Journal of Clinical Oncology, 2013, 31, 3957-3963.	0.8	87
12	Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer. Drug Design, Development and Therapy, 2014, 8, 667.	2.0	11
13	The diagnosis and treatment of brain metastases in EGFR mutant lung cancer. CNS Oncology, 2014, 3, 209-217.	1.2	2
14	Controversies in the management of stage III non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2014, 14, 333-347.	1.1	14
16	Targeting Angiogenesis in Squamous Non-Small Cell Lung Cancer. Drugs, 2014, 74, 403-413.	4.9	84
17	Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer. Annals of Oncology, 2014, 25, 121-126.	0.6	27
18	Intracranial Disease in Patients with Non-Small Cell Lung Cancer. , 2014, , 169-179.		0
19	Interaction of Radiation Therapy With Molecular Targeted Agents. Journal of Clinical Oncology, 2014, 32, 2886-2893.	0.8	77
20	Molecular targeted therapy for early-stage non-small-cell lung cancer: Will it increase the cure rate?. Lung Cancer, 2014, 84, 97-100.	0.9	19

#	Article	IF	Citations
21	Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors. Translational Oncology, 2014, 7, 400-409.	1.7	15
24	Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 317-324.	0.4	59
25	Combining Systemic Therapies with Radiation in Non-Small Cell Lung Cancer. Journal of Cancer Science & Therapy, 2015, 07, .	1.7	1
26	A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Nonâ€“Small-Cell Lung Cancer: SWOG S0533. Clinical Lung Cancer, 2015, 16, 340-347.	1.1	42
27	Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer. Radiotherapy and Oncology, 2015, 114, 161-166.	0.3	30
28	The Role of Anti-angiogenesis in Non-small-cell Lung Cancer: an Update. Current Oncology Reports, 2015, 17, 26.	1.8	44
29	Molecular Determinants of Radiation Response in Nonâ€“Small Cell Lung Cancer. Seminars in Radiation Oncology, 2015, 25, 67-77.	1.0	8
30	Repression of the autophagic response sensitises lung cancer cells to radiation and chemotherapy. British Journal of Cancer, 2016, 115, 312-321.	2.9	28
31	Radio(chemo)therapy in locally advanced nonsmall cell lung cancer. European Respiratory Review, 2016, 25, 65-70.	3.0	24
32	Biologics and Their Interactions with Radiation. , 2016, , 80-92.e4.		0
33	Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). Clinical and Translational Oncology, 2017, 19, 31-43.	1.2	19
34	STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma. Clinical Cancer Research, 2017, 23, 3442-3452.	3.2	15
35	Cardiac Toxicity After Radiotherapy for Stage III Nonâ€“Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. Journal of Clinical Oncology, 2017, 35, 1387-1394.	0.8	318
36	From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?. Expert Review of Anticancer Therapy, 2017, 17, 157-165.	1.1	0
37	Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Nonâ€“Small-Cell Lung Cancer. JAMA Oncology, 2017, 3, 1120.	3.4	93
38	Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. Radiotherapy and Oncology, 2017, 125, 293-300.	0.3	91
39	Management of stage III nonâ€“small cell lung cancer. Seminars in Oncology, 2017, 44, 163-177.	0.8	40
40	Evaluation at 3Âyears of concurrent bevacizumab and radiotherapy for breast cancer: Results of a prospective study. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2018, 22, 222-228.	0.6	3

#	Article	IF	Citations
41	Metformin for non-small cell lung cancer patients: Opportunities and pitfalls. Critical Reviews in Oncology/Hematology, 2018, 125, 41-47.	2.0	32
42	Treatment of locally advanced, unresectable or medically inoperable stage III non-small-cell lung cancer; the past, present and future of chemoradiotherapy. Journal of Oncological Science, 2018, 4, 49-52.	0.1	2
43	Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Nonâ€“Small-cell Lung Cancer: A Phase I Study. Clinical Lung Cancer, 2018, 19, e277-e285.	1.1	19
44	Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?. Journal of Thoracic Disease, 2018, 10, S1461-S1467.	0.6	25
45	Toxicity of locoregional radiotherapy in combination with bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation. PLoS ONE, 2019, 14, e0221816.	1.1	6
46	Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib. BMC Cancer, 2019, 19, 901.	1.1	33
47	Combination of novel systemic agents and radiotherapy for solid tumors â€“ Part II: An AIRO (Italian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Reviews in Oncology/Hematology, 2019, 134, 104-119.	2.0	10
48	Improving the Efficacy of Tumor Radiosensitization Through Combined Molecular Targeting. Frontiers in Oncology, 2020, 10, 1260.	1.3	15
49	Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Nonâ€“Small-Cell LungÂCancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). Clinical Lung Cancer, 2020, 21, 520-526.	1.1	8
50	Immunotherapy and Radiation Therapy for Non-Small Cell Lung Cancerâ€”A Stimulating Partnership. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 360-368.	0.8	2
51	The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer. International Journal of Cancer, 2020, 147, 1163-1179.	2.3	16
52	Tracheoesophageal fistula associated with bevacizumab after thoracic radiotherapy in non-small cell lung cancer. Medicine (United States), 2020, 99, e19878.	0.4	5
53	Concurrent Chemo-Proton Therapy Using Adaptive Planning for Unresectable Stage 3 Non-Small Cell Lung Cancer: A Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1359-1367.	0.4	13
54	Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1349-1358.	0.4	35
55	Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents. Translational Lung Cancer Research, 2021, 10, 2032-2047.	1.3	12
56	Targeted therapies for unresectable stage III non-small cell lung cancer. Mediastinum, 2021, 5, 22-22.	0.6	7
57	Biologics and Their Interactions with Radiation. , 2012, , 83-94.		1
58	A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer. Oncotarget, 2017, 8, 15924-15933.	0.8	16

#	Article	IF	Citations
59	Bevacizumab-induced tracheoesophageal fistula in a patient suffering from lung cancer with bulky subcarinal lymph node: a case report. Nagoya Journal of Medical Science, 2018, 80, 129-134.	0.6	11
60	Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study. Translational Cancer Research, 2018, 7, S16-S20.	0.4	4
61	Combining Anti-Epidermal Growth Factor Receptor (EGFR) and Anti-Angiogenic Strategies in Advanced NSCLC: We Should have Known Betterâ€¦. Current Pharmaceutical Design, 2014, 20, 3901-3913.	0.9	7
62	Hispidulin exhibits potent anticancer activity inï¿½vitro and inï¿½vivo through activating ER stress in nonâ€‘smallâ€‘cell lung cancer cells. Oncology Reports, 2020, 43, 1995-2003.	1.2	18
63	Therapeutic integration of new molecule-targeted therapies with radiotherapy in lung cancer. Translational Lung Cancer Research, 2014, 3, 89-94.	1.3	16
64	Tracheal Diverticulum Following Paratracheal Hypofractionated Radiotherapy in the Setting of Prior and Subsequent Bevacizumab. Cureus, 2016, 8, e578.	0.2	2
65	Locally Advanced Non-small Cell Lung Cancer and Targeted Therapy. , 2017, , 155-165.		0
66	Radiation Therapy in Non-small-Cell Lung Cancer. , 2019, , 1-55.		0
67	Immunotherapy for Lung Cancerâ€"Improving Outcomes in Patients With Locally Advanced Nonâ€“Small Cell Lung Cancer With Immunotherapy. Cancer Journal (Sudbury, Mass), 2020, 26, 548-554.	1.0	2
68	The Daniel K. Inouye College of Pharmacy Scripts: Targeted Nanocarrier Based Systems for the Treatment of Lung Cancer. Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health, 2017, 76, 318-325.	0.4	0
70	The ADAM17-directed Inhibitory Antibody MEDI3622 Antagonizes Radiotherapy-induced VEGF Release and Sensitizes Nonâ€“Small Cell Lung Cancer for Radiotherapy. Cancer Research Communications, 2021, 1, 164-177.	0.7	7
73	Severe Pulmonary Toxicity with Concurrent Anlotinib And Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: The ALTER-L042 Phase I Clinical Trial. JTO Clinical and Research Reports, 2022, , 100339.	0.6	0
74	Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis. Future Oncology, 0, , .	1.1	1